ArticleBMC gastroenterology2026
Clinicopathological features of hepatobiliary cells in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe underlying mechanisms of incomplete response to ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC) remain unclear. This study aimed to investigate the clinicopathological characteristics and potential mechanisms of hepatobiliary (HB) cells in PBC patients with an incomplete response to UDCA.
methodsA total of 132 PBC patients who underwent ultrasound-guided liver biopsy were enrolled. Liver tissue samples were processed using multiple histochemical staining methods. Demographic, clinical, hematological, autoantibody, and biochemical data were retrospectively analyzed. The therapeutic response to UDCA was evaluated according to the Paris II criteria. Additionally, bile acid metabolomic profiling was performed using liquid chromatography-mass spectrometry (LC-MS) on paraffin-embedded liver tissues from 25 randomly selected PBC patients.
resultsAmong the 132 patients, 58 (43.9%) exhibited an incomplete response to UDCA. The number of CK7⁺ HB cells, degree of hepatocellular copper deposition, levels of alkaline phosphatase (ALP), total bile acid (TBA), and anti-GP210 antibody were significantly associated with incomplete response to UDCA. These factors exhibited AUC values of 0.745, 0.678, 0.809, 0.770 and 0.588, respectively. Hepatic levels of TBA (p = 0.010) and glycoursodeoxycholic acid (GUDCA, p = 0.037) were significantly higher in the incomplete response group compared with the complete response group. Moreover, the abundance of CK7⁺ HB cells was positively correlated with hepatic TBA (r = 0.544, p < 0.01) and GUDCA (r = 0.480, p < 0.05) levels.
conclusionsPBC patients with an incomplete response to UDCA exhibited a significant increase in CK7⁺ HB cells, which were independently associated with treatment incomplete response. Although biochemical parameters such as ALP and TBA remain key predictors of incomplete response to UDCA, CK7⁺ HB cells provide additional histological insights into the mechanisms underlying incomplete therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.